Robert Iannone - Jan 17, 2024 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
EVP, Global Head of R&D
Signature
By: /s/Adam Guttmann, as attorney in fact For: Robert Iannone
Stock symbol
JAZZ
Transactions as of
Jan 17, 2024
Transactions value $
-$206,095
Form type
4
Date filed
1/19/2024, 06:25 PM
Previous filing
Jun 15, 2023
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Award $0 +5.97K +13.16% $0.00 51.3K Jan 17, 2024 Direct F1, F2
transaction JAZZ Ordinary Shares Tax liability -$206K -1.73K -3.37% $119.13 49.6K Jan 17, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified.
F2 The Reporting Person acquired 37 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 30, 2023.
F3 Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations.